AnaptysBio Recruits Ex-Pfizer (PFE) R&D Star to Lead Translational Biology

Anaptysbio Recruits Dr. Gerrit Los To Lead Translational Biology

Adds Immuno-Oncology Development Strength to AnaptysBio's Product Pipeline

SAN DIEGO, Calif. – AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Gerrit Los, Ph.D. as Vice President of Pharmacology. Dr. Los will lead translational biology across AnaptysBio's proprietary antibody pipeline, including programs focused upon novel immuno-oncology opportunities. Dr. Los will report to Dr. Marco Londei, AnaptysBio's Chief Development Officer.

"We are thrilled to welcome Dr. Los to AnaptysBio's product development team and look forward to his contribution to the multiple antibody programs advancing to the clinic over the next 18 months," said Hamza Suria, President and Chief Executive Officer of AnaptysBio. "Progressing our pipeline assets through to clinical proof-of-concept is a strategic priority for AnaptysBio and Dr. Los' translational research depth will provide key support to our upcoming value inflection events. By coupling this development team to our antibody generation platform, AnaptysBio is strongly positioned to continue building its pipeline of therapeutics across emerging inflammation and immuno-oncology applications."

Dr. Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics. Prior to Five Prime, Dr. Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib. Prior to Pfizer, Dr. Los was an Adjunct Professor at the University of California San Diego where his work focused on identifying response markers in cancer. Dr. Los received his Ph.D. in Pharmacology from the Free University in Amsterdam, Netherlands and was a Dutch Cancer Society post-doctoral fellow at the Netherlands Cancer Institute. Dr. Los has published more than 100 peer-reviewed papers and is recognized as a leading expert in immuno-oncology and pharmacology.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.